Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Kirkwood, John M.; Vecchio, Michele Del; Weber, Jeffrey S.; Höeller, Christoph; Grob, Jean‐Jacques; Mohr, Peter; Loquai, Carmen; Dutriaux, Caroline; Chiarion‐Sileni, Vanna; Mackiewicz, Jacek; Rutkowski, Piotr; Arenberger, Petr; Quéreux, G.; Meniawy, Tarek; Ascierto, Paolo A.; Menzies, Alexander M.; Durani, Piyush; Lobo, Maurice; Campigotto, Federico; Gastman, Brian; Long, Georgina V.

doi:10.1038/s41591-023-02583-2

articleNature MedicineOct 16, 2023HYBRID OA

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

JMJohn M. Kirkwood MDMichele Del Vecchio JSJeffrey S. Weber CHChristoph Höeller JGJean‐Jacques Grob

UPMC Health System · UPMC Hillman Cancer Center · +22 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The primary endpoint was investigator-assessed recurrence-free survival (RFS). Secondary endpoints included distant metastasis-free survival (DMFS) and safety. At 7.8 months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR) = 0.42; 95% confidence interval (CI): 0.30-0.59; P

Citation impact

194

total citations

FWCI: 42.00
Percentile: 100%
References: 30

Citations per year

Authors

21

Topics & keywords

Topics

Keywords

Nivolumab
Medicine
Hazard ratio
Internal medicine
Placebo
Clinical endpoint
Adverse effect
Adjuvant

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.